Related Experiment Video
Updated: Sep 7, 2025
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
Pediatric Kidney Transplantation-Can We Do Better? The Promise and Limitations of Epitope/Eplet Matching
Olga Charnaya1, Daniella Levy Erez2,3, Sandra Amaral3
1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Insights
Kidney transplant outcomes are limited by donor specific antibodies (dnDSA). Epitope matching offers a promising strategy for primary prevention of dnDSA, potentially improving long-term graft survival in pediatric patients.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Kidney transplantation is the preferred treatment for end-stage kidney disease, offering better survival and quality of life than dialysis.
- Despite advances, long-term kidney graft survival has stagnated, particularly in children who often require multiple transplants.
- The development of de novo donor-specific HLA antibodies (dnDSA) complicates re-transplantation, increasing mortality and morbidity.
Purpose of the Study:
- To review the potential of epitope matching as a primary prevention strategy for dnDSA in pediatric kidney transplantation.
- To discuss the current state, strengths, and limitations of epitope matching software in clinical practice.
- To explore the evidence supporting epitope matching for improving long-term allograft outcomes and address potential population disparities.
Main Methods:
- Review of current literature on epitope matching software and its application in kidney transplantation.
- Analysis of evidence regarding the impact of epitope matching on dnDSA formation and graft survival.
- Discussion of eplet load, immunogenicity, and the balance between improved matching and equitable access.
Main Results:
- Epitope matching offers a more refined assessment of immunological compatibility than traditional HLA matching.
- Current evidence for improved outcomes with epitope matching is still developing, with ongoing debate.
- No FDA-approved therapies effectively reduce dnDSA burden or improve long-term outcomes.
Conclusions:
- Primary prevention of dnDSA through improved donor selection, such as epitope matching, is crucial for enhancing long-term kidney allograft survival in children.
- Further research and clinical implementation of epitope matching are needed to optimize donor selection and mitigate risks associated with over-immunosuppression.
- Balancing the benefits of advanced matching strategies with equitable access for all patient populations is essential.
Abstract:
Kidney transplant is the optimal treatment for end-stage kidney disease as it offers significant survival and quality of life advantages over dialysis. While recent advances have significantly improved early graft outcomes, long-term overall graft survival has remained largely unchanged for the last 20 years. Due to the young age at which children receive their first transplant, most children will require multiple transplants during their lifetime. Each subsequent transplant becomes more difficult because of the development of de novo donor specific HLA antibodies (dnDSA), thereby limiting the donor pool and increasing mortality and morbidity due to longer time on dialysis awaiting re-transplantation. Secondary prevention of dnDSA through increased post-transplant immunosuppression in children is constrained by a significant risk for viral and oncologic complications. There are currently no FDA-approved therapies that can meaningfully reduce dnDSA burden or improve long-term allograft outcomes. Therefore, primary prevention strategies aimed at reducing the risk of dnDSA formation would allow for the best possible long-term allograft outcomes without the adverse complications associated with over-immunosuppression. Epitope matching, which provides a more nuanced assessment of immunological compatibility between donor and recipient, offers the potential for improved donor selection. Although epitope matching is promising, it has not yet been readily applied in the clinical setting. Our review will describe current strengths and limitations of epitope matching software, the evidence for and against improved outcomes with epitope matching, discussion of eplet load vs. variable immunogenicity, and conclude with a discussion of the delicate balance of improving matching without disadvantaging certain populations.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:40Cell-mediated Immune Responses